Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Neuronetics ( (STIM) ).
On December 30, 2025, Neuronetics, Inc.’s compensation committee approved significant cash and restricted stock unit incentive awards for two senior executives, Executive Vice President, Chief Financial Officer and Treasurer Steven E. Pfanstiel and Executive Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary W. Andrew Macan, granting them cash bonuses of $240,000 and $231,750, respectively, and 170,212 and 164,361 RSUs, respectively. The awards, which will be paid and will fully vest on the earlier of June 30, 2027 or a termination of employment without cause, underscore the company’s focus on retaining key leadership and aligning executive incentives with long-term corporate performance, potentially strengthening management stability during a critical period for its strategic and financial execution.
The most recent analyst rating on (STIM) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Neuronetics stock, see the STIM Stock Forecast page.
Spark’s Take on STIM Stock
According to Spark, TipRanks’ AI Analyst, STIM is a Neutral.
Neuronetics’ overall stock score is primarily impacted by its financial challenges and bearish technical indicators. The company’s ongoing profitability issues and reliance on external financing are significant risks. While there is some positive momentum from revenue growth and operational improvements, these are overshadowed by valuation concerns and technical weaknesses.
To see Spark’s full report on STIM stock, click here.
More about Neuronetics
Neuronetics, Inc. operates in the medical technology sector, focusing on neurohealth treatments. The company develops and commercializes non-invasive therapies, notably transcranial magnetic stimulation systems, targeting psychiatric and neurological disorders through partnerships with healthcare providers.
Average Trading Volume: 1,596,561
Technical Sentiment Signal: Sell
Current Market Cap: $96.57M
For a thorough assessment of STIM stock, go to TipRanks’ Stock Analysis page.